| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:NDUFA7_PRKCG |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: NDUFA7_PRKCG | KinaseFusionDB ID: KFG4089 | FusionGDB2.0 ID: KFG4089 | Hgene | Tgene | Gene symbol | NDUFA7 | PRKCG | Gene ID | 4701 | 5582 | |
| Gene name | NADH:ubiquinone oxidoreductase subunit A7 | protein kinase C gamma | ||||||||||
| Synonyms | B14.5a|CI-B14.5a | PKC-gamma|PKCC|PKCG|PKCI(3)|PKCgamma|SCA14 | ||||||||||
| Cytomap | 19p13.2 | 19q13.42 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7, 14.5kDaNADH-ubiquinone oxidoreductase subunit B14.5acomplex I B14.5a subunit | protein kinase C gamma type | ||||||||||
| Modification date | 20240411 | 20240403 | ||||||||||
| UniProtAcc | O95182 | P05129 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000301457, ENST00000598884, | ENST00000263431, ENST00000536044, ENST00000540413, ENST00000542049, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: NDUFA7 [Title/Abstract] AND PRKCG [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | NDUFA7(8381380)-PRKCG(54406327), # samples:4 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | PRKCG | GO:0016310 | phosphorylation | 15808853 |
| Tgene | PRKCG | GO:0031397 | negative regulation of protein ubiquitination | 15808853 |
| Tgene | PRKCG | GO:0032425 | positive regulation of mismatch repair | 15808853 |
| Tgene | PRKCG | GO:0042177 | negative regulation of protein catabolic process | 15808853 |
| Kinase Fusion gene breakpoints across NDUFA7 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across PRKCG (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChimerDB4 | TCGA-D6-6515-01A | NDUFA7 | chr19 | 8381380 | PRKCG | chr19 | 54406327 |
| ChimerDB4 | TCGA-D6-6515 | NDUFA7 | chr19 | 8381379 | PRKCG | chr19 | 54406326 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:8381380/:54406327) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| NDUFA7 | PRKCG |
| FUNCTION: Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone. {ECO:0000269|PubMed:27626371}. | FUNCTION: Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays diverse roles in neuronal cells and eye tissues, such as regulation of the neuronal receptors GRIA4/GLUR4 and GRIN1/NMDAR1, modulation of receptors and neuronal functions related to sensitivity to opiates, pain and alcohol, mediation of synaptic function and cell survival after ischemia, and inhibition of gap junction activity after oxidative stress. Binds and phosphorylates GRIA4/GLUR4 glutamate receptor and regulates its function by increasing plasma membrane-associated GRIA4 expression. In primary cerebellar neurons treated with the agonist 3,5-dihyidroxyphenylglycine, functions downstream of the metabotropic glutamate receptor GRM5/MGLUR5 and phosphorylates GRIN1/NMDAR1 receptor which plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. May be involved in the regulation of hippocampal long-term potentiation (LTP), but may be not necessary for the process of synaptic plasticity. May be involved in desensitization of mu-type opioid receptor-mediated G-protein activation in the spinal cord, and may be critical for the development and/or maintenance of morphine-induced reinforcing effects in the limbic forebrain. May modulate the functionality of mu-type-opioid receptors by participating in a signaling pathway which leads to the phosphorylation and degradation of opioid receptors. May also contributes to chronic morphine-induced changes in nociceptive processing. Plays a role in neuropathic pain mechanisms and contributes to the maintenance of the allodynia pain produced by peripheral inflammation. Plays an important role in initial sensitivity and tolerance to ethanol, by mediating the behavioral effects of ethanol as well as the effects of this drug on the GABA(A) receptors. During and after cerebral ischemia modulate neurotransmission and cell survival in synaptic membranes, and is involved in insulin-induced inhibition of necrosis, an important mechanism for minimizing ischemic injury. Required for the elimination of multiple climbing fibers during innervation of Purkinje cells in developing cerebellum. Is activated in lens epithelial cells upon hydrogen peroxide treatment, and phosphorylates connexin-43 (GJA1/CX43), resulting in disassembly of GJA1 gap junction plaques and inhibition of gap junction activity which could provide a protective effect against oxidative stress (By similarity). Phosphorylates p53/TP53 and promotes p53/TP53-dependent apoptosis in response to DNA damage. Involved in the phase resetting of the cerebral cortex circadian clock during temporally restricted feeding. Stabilizes the core clock component BMAL1 by interfering with its ubiquitination, thus suppressing its degradation, resulting in phase resetting of the cerebral cortex clock (By similarity). {ECO:0000250|UniProtKB:P63318, ECO:0000250|UniProtKB:P63319, ECO:0000269|PubMed:16377624}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of NDUFA7_PRKCG |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| PRKCG | P05129 | human | HSP90AA1 | P07900 | T115 | GtIAksGtkAFMEAL | HATPase_c |
| PRKCG | P05129 | human | DNAJC5 | Q9H3Z4 | S34 | TSDDIKKsYRKLALk | DnaJ |
| PRKCG | P05129 | human | MAPT | P10636-8 | S352 | DFKDrVQskIGsLDN | Tubulin-binding |
| PRKCG | P05129 | human | DAB2 | P98082 | S24 | QAAPKAPsKKEKKKG | |
| PRKCG | P05129 | human | KCNC4 | Q03721 | S9 | ISSVCVssYRGRKsG | Potassium_chann |
| PRKCG | P05129 | human | KCNC4 | Q03721 | S21 | KsGNKPPsKTCLKEE | Potassium_chann |
| PRKCG | P05129 | human | HSP90AA1 | P07900 | T425 | KkCLELFtELAEDkE | HSP90 |
| PRKCG | P05129 | human | MAPT | P10636-8 | S324 | kVTskCGsLGNIHHk | Tubulin-binding |
| PRKCG | P05129 | human | CHAT | P28329-3 | S440 | VPTYESAsIRRFQEG | Carn_acyltransf |
| PRKCG | P05129 | human | CHAT | P28329-3 | S347 | LKHVTQssRKLIRAD | Carn_acyltransf |
| PRKCG | P05129 | human | NGFR | P08138 | S277 | IAFKRWNsCKQNKQG | TNFR_16_TM |
| PRKCG | P05129 | human | CHAT | P28329-3 | T255 | TVLVKDStNRDSLDM | Carn_acyltransf |
| PRKCG | P05129 | human | MAPT | P10636-8 | S293 | NVQskCGsKDNIkHV | Tubulin-binding |
| PRKCG | P05129 | human | GSK3A | P49840 | S21 | sGrARtssFAEPGGG | |
| PRKCG | P05129 | human | MAPT | P10636-8 | S258 | PDLkNVKskIGstEN | Tubulin-binding |
| PRKCG | P05129 | human | KCNC4 | Q03721 | S8 | MISSVCVssYRGRKs | Potassium_chann |
| PRKCG | P05129 | human | NADK | O95544 | S64 | kEFRRtRsLHGPCPV | |
| PRKCG | P05129 | human | KIR3DL1 | P43629 | S415 | QRKITRPsQRPKtPP | |
| PRKCG | P05129 | human | GSK3B | P49841 | S9 | SGRPRttsFAEsCkP | |
| PRKCG | P05129 | human | TRPC3 | Q13507 | T646 | LQISLGRtVKDIFKF | Ion_trans |
| PRKCG | P05129 | human | MMP14 | P50281 | T567 | FFFRRHGtPRRLLyC | DUF3377 |
| PRKCG | P05129 | human | RPS6KB2 | Q9UBS0 | S473 | PPSGTKKsKRGRGRP | |
| PRKCG | P05129 | human | ARHGEF7 | Q14155 | S518 | LSASPRMsGFIYQGK | PH |
| PRKCG | P05129 | human | GRK2 | P25098 | S29 | ATPAARAskkILLPE | |
| PRKCG | P05129 | human | C5AR1 | P21730 | S334 | sVVREsKsFTRsTVD | |
| PRKCG | P05129 | human | KCNC4 | Q03721 | S15 | ssYRGRKsGNKPPsK | Potassium_chann |
| PRKCG | P05129 | human | DNAJC5 | Q9H3Z4 | S10 | DQRQRsLstsGEsLy | |
| PRKCG | P05129 | human | APTX | Q7Z2E3 | T125 | AKNPGLEtHRKRKRs | |
| PRKCG | P05129 | human | CD5 | P06127 | T434 | MsFHRNHtAtVRsHA | |
| PRKCG | P05129 | human | CHAT | P28329-3 | S476 | HKAAVPAsEKLLLLK | Carn_acyltransf |
| PRKCG | P05129 | human | HSP90AA1 | P07900 | T603 | PCCIVtstyGWtANM | HSP90 |
| PRKCG | P05129 | human | CHAT | P28329-3 | S346 | LLKHVTQssRKLIRA | Carn_acyltransf |
| PRKCG | P05129 | human | ARHGEF7 | Q14155 | S761 | DSLGRRSsLsRLEPS | |
| PRKCG | P05129 | human | CD5 | P06127 | T436 | FHRNHtAtVRsHAEN | |
| PRKCG | P05129 | human | NADK | O95544 | S46 | RGRAKsrsLsAsPAL |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| PRKCG | ID | Description | 0.00e+00 |
| PRKCG | GO:0045862 | positive regulation of proteolysis | 9.91e-04 |
| PRKCG | GO:1903829 | positive regulation of protein localization | 2.48e-03 |
| PRKCG | GO:0016049 | cell growth | 2.48e-03 |
| PRKCG | GO:0018105 | peptidyl-serine phosphorylation | 2.48e-03 |
| PRKCG | GO:0018209 | peptidyl-serine modification | 2.48e-03 |
| PRKCG | GO:0009266 | response to temperature stimulus | 4.07e-03 |
| PRKCG | GO:1902074 | response to salt | 4.07e-03 |
| PRKCG | GO:0034605 | cellular response to heat | 4.83e-03 |
| PRKCG | GO:0032388 | positive regulation of intracellular transport | 4.83e-03 |
| PRKCG | GO:0070874 | negative regulation of glycogen metabolic process | 4.83e-03 |
| PRKCG | GO:0001558 | regulation of cell growth | 4.83e-03 |
| PRKCG | GO:0045732 | positive regulation of protein catabolic process | 4.85e-03 |
| PRKCG | GO:0010810 | regulation of cell-substrate adhesion | 5.17e-03 |
| PRKCG | GO:1901030 | positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway | 5.17e-03 |
| PRKCG | GO:1902947 | regulation of tau-protein kinase activity | 5.70e-03 |
| PRKCG | GO:0048588 | developmental cell growth | 6.01e-03 |
| PRKCG | GO:0090257 | regulation of muscle system process | 6.42e-03 |
| PRKCG | GO:0032436 | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 6.76e-03 |
| PRKCG | GO:1900034 | regulation of cellular response to heat | 6.91e-03 |
| PRKCG | GO:0009408 | response to heat | 8.24e-03 |
| PRKCG | GO:2000060 | positive regulation of ubiquitin-dependent protein catabolic process | 1.03e-02 |
| PRKCG | GO:1901800 | positive regulation of proteasomal protein catabolic process | 1.05e-02 |
| PRKCG | GO:0051222 | positive regulation of protein transport | 1.05e-02 |
| PRKCG | GO:0007006 | mitochondrial membrane organization | 1.05e-02 |
| PRKCG | GO:0048675 | axon extension | 1.05e-02 |
| PRKCG | GO:0010811 | positive regulation of cell-substrate adhesion | 1.05e-02 |
| PRKCG | GO:0072655 | establishment of protein localization to mitochondrion | 1.05e-02 |
| PRKCG | GO:0003323 | type B pancreatic cell development | 1.05e-02 |
| PRKCG | GO:1904951 | positive regulation of establishment of protein localization | 1.05e-02 |
| PRKCG | GO:0048143 | astrocyte activation | 1.05e-02 |
| PRKCG | GO:0070585 | protein localization to mitochondrion | 1.05e-02 |
| PRKCG | GO:1901028 | regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway | 1.05e-02 |
| PRKCG | GO:1905523 | positive regulation of macrophage migration | 1.05e-02 |
| PRKCG | GO:0032386 | regulation of intracellular transport | 1.05e-02 |
| PRKCG | GO:1903052 | positive regulation of proteolysis involved in protein catabolic process | 1.11e-02 |
| PRKCG | GO:0090090 | negative regulation of canonical Wnt signaling pathway | 1.11e-02 |
| PRKCG | GO:0032434 | regulation of proteasomal ubiquitin-dependent protein catabolic process | 1.11e-02 |
| PRKCG | GO:1900180 | regulation of protein localization to nucleus | 1.11e-02 |
| PRKCG | GO:0031346 | positive regulation of cell projection organization | 1.11e-02 |
| PRKCG | GO:0031589 | cell-substrate adhesion | 1.11e-02 |
| PRKCG | GO:0003309 | type B pancreatic cell differentiation | 1.14e-02 |
| PRKCG | GO:0042176 | regulation of protein catabolic process | 1.14e-02 |
| PRKCG | GO:0005979 | regulation of glycogen biosynthetic process | 1.14e-02 |
| PRKCG | GO:0010962 | regulation of glucan biosynthetic process | 1.14e-02 |
| PRKCG | GO:0010821 | regulation of mitochondrion organization | 1.14e-02 |
| PRKCG | GO:0019082 | viral protein processing | 1.14e-02 |
| PRKCG | GO:0099171 | presynaptic modulation of chemical synaptic transmission | 1.14e-02 |
| PRKCG | GO:0090316 | positive regulation of intracellular protein transport | 1.21e-02 |
| PRKCG | GO:0070507 | regulation of microtubule cytoskeleton organization | 1.25e-02 |
Top |
Related Drugs to NDUFA7_PRKCG |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning NDUFA7-PRKCG and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to NDUFA7_PRKCG |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |